iBio, Inc.
IBIO
NASDAQ·Healthcare·Biotechnology·Mkt cap $19.9M
$1.32
▲ +4.76%
P/E
-2.31
Mkt Cap
$19.9M
52-Wk Range
$0.77–$3.82
52-Week Range
$0.77 - $3.82
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 55.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary bioprocessing technology platform
- Strategic partnerships with Texas A&M and academic institutions
- Established CDMO infrastructure and manufacturing capabilities
- Diversified pipeline across therapeutic and vaccine candidates
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Expansion of contract manufacturing demand from biotech partners
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-28.4% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IBIO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 29, 2026
AUG 28, 2026
Reported EPS of -$0.04 vs -$0.07 consensus (+39.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+39.0%
Revenue trend · last 8Q
—
—
—
—
+14%
—
-100%
—
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q4 26
$175.0K
$0
$200.0K
$0
$200.0K
$100.0K
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Raymond James · Jun 8, 2026
vs Industry
How IBIO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related